ANGIOTENSIN-II RECEPTOR BLOCKADE AFTER MYOCARDIAL-INFARCTION IN RATS - EFFECTS ON HEMODYNAMICS, MYOCARDIAL DNA-SYNTHESIS, AND INTERSTITIAL COLLAGEN CONTENT

被引:186
作者
SMITS, JFM [1 ]
VANKRIMPEN, C [1 ]
SCHOEMAKER, RG [1 ]
CLEUTJENS, JPM [1 ]
DAEMEN, MJAP [1 ]
机构
[1] UNIV LIMBURG, DEPT PATHOL, 6200 MD MAASTRICHT, NETHERLANDS
关键词
LOSARTAN; CARDIAC FUNCTION; CARDIAC STRUCTURE; HEART FAILURE;
D O I
10.1097/00005344-199220050-00013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Angiotensin-converting enzyme (ACE) inhibitors are widely used for treatment of heart failure after myocardial infarction (MI). The beneficial effects consist of a combination of hemodynamic effects and interference with cardiac structural alterations. These effects are believed to depend on inhibition of angiotensin II (AII) formation and thus diminished angiotensin receptor stimulation. We administered the angiotensin II-1 (AT-1) receptor antagonist losartan during and after completion of the repair phase of an MI to investigate involvement of the AT-1 receptor in the above described effects of captopril. MI reduced cardiac output (CO) (sham 94 +/- 4 ml/min, MI 78 +/- 5 ml/min) and maximal CO (sham 154 +/- 4, MI 107 +/- 5 ml/min, respectively). Losartan (15 mg/kg/day) resulted in a rightward shift of the AII pressor dose-response curve by a factor of 32-40. Neither CO nor CO(VL,max) was affected by losartan treatment in either phase (late treatment CO = 78 +/- 5, CO(VL,max) = 118 +/- 9 ml/min). Although early treatment with losartan reduced cardiac hypertrophy measured as heart weight, DNA synthesis was reduced only slightly. In contrast, collagen deposition was inhibited completely. The results suggest that the effects of captopril in rats after MI are not dependent on AT-1 receptor-mediated mechanisms.
引用
收藏
页码:772 / 778
页数:7
相关论文
共 43 条
[1]   PHARMACOLOGICAL INTERFERENCE WITH THE CARDIAC RENIN-ANGIOTENSIN SYSTEM [J].
BECKER, RHA ;
LINZ, W ;
SCHOLKENS, BA .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1989, 14 :S10-S15
[2]  
CHIU AT, 1990, J PHARMACOL EXP THER, V252, P711
[3]   IDENTIFICATION OF ANGIOTENSIN-II RECEPTOR SUBTYPES [J].
CHIU, AT ;
HERBLIN, WF ;
MCCALL, DE ;
ARDECKY, RJ ;
CARINI, DJ ;
DUNCIA, JV ;
PEASE, LJ ;
WONG, PC ;
WEXLER, RR ;
JOHNSON, AL ;
TIMMERMANS, PBMWM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 165 (01) :196-203
[4]   NON-PEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONISTS .2. PHARMACOLOGY OF S-8308 [J].
CHIU, AT ;
CARINI, DJ ;
JOHNSON, AL ;
MCCALL, DE ;
PRICE, WA ;
THOOLEN, MJMC ;
WONG, PC ;
TABER, RI ;
TIMMERMANS, PBMWM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 157 (01) :13-21
[5]  
CHIU AT, 1990, FASEB J, V4, pA1113
[6]   PICROSIRIUS RED STAINING OF CARDIAC-MUSCLE FOLLOWING PHOSPHOMOLYBDIC ACID TREATMENT [J].
DOLBER, PC ;
SPACH, MS .
STAIN TECHNOLOGY, 1987, 62 (01) :23-26
[7]   HYDROLYSIS OF BRADYKININ AND ITS HIGHER HOMOLOGS BY ANGIOTENSIN-CONVERTING ENZYME [J].
DORER, FE ;
RYAN, JW ;
STEWART, JM .
BIOCHEMICAL JOURNAL, 1974, 141 (03) :915-917
[9]  
FISHBEIN MC, 1978, AM J PATHOL, V90, P57
[10]  
HERBLIN WF, 1990, FASEB J, V4, pA1113